When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials
- PMID: 32814685
- DOI: 10.1016/j.euo.2020.07.005
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials
Abstract
Context: The goal of precision oncology is to use the underlying genomic characteristics of the patient and the cancer to select the optimal treatment at a given time. The recent Food and Drug Administration (FDA) approval of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib for the treatment of advanced prostate cancer heralds the onset of precision medicine for this disease.
Objective: To discuss the emerging role that PARP inhibitors may play as a personalised future treatment option in patients with prostate cancer, with a focus on patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumour cells harbour mutations resulting from deficient homologous recombination repair (HRR).
Evidence acquisition: To identify publications relevant to this review, a systematic literature search of PubMed was conducted for articles and proceedings of relevant major congresses, published between January 2010 and March 2020, reporting the use of PARP inhibitors in the treatment of cancers.
Evidence synthesis: A total of 168 publications were identified, and 18 of these met the criteria for subsequent review. In addition, 15 phase 2 or on-going phase 3 (mCRPC) studies evaluating PARP inhibitors as monotherapy or in combination, which had not yet reported data, were identified through ClinicalTrials.gov. Emerging data suggest that the greatest efficacy with single-agent PARP inhibitors is seen in mCRPC patients with germline or somatic BRCA1/2 alterations (especially BRCA2 or biallelic mutations), with potential efficacy also observed in men with PALB2 and FANCA mutations.
Conclusions: PARP inhibitors have demonstrated efficacy in mCRPC, and similar to ovarian and breast cancers, the greatest effect is observed in patients with HRR deficiency. The PARP inhibitors olaparib and rucaparib are now FDA approved for mCRPC patients with HRR mutations and BRCA1/2 mutations, respectively. Furthermore, when PARP inhibition is combined with novel hormonal therapies, a treatment benefit may be observed regardless of the HRR deficiency status. Gaps in the knowledge and understanding around PARP inhibitor use in prostate cancer, including the most appropriate diagnostic testing method for identifying an HRR mutation, remain to be resolved.
Patient summary: The poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib are now approved by the Food and Drug Administration for the treatment of advanced prostate cancer. Here, we reviewed the literature and proceedings from meeting presentations and published papers relevant to the use of PARP inhibitors in the treatment of prostate cancer. Testing methods for detecting homologous recombination repair gene mutations, as diagnostic tools to help identify patients most likely to benefit from PARP inhibitor treatment, are also discussed.
Keywords: Homologous recombination repair; Niraparib; Olaparib; Poly(ADP-ribose) polymerase inhibitor; Prostate cancer; Rucaparib.
Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
Comment in
-
PARP Inhibitors in Prostate Cancer: A Promise Delivered.Eur Urol Oncol. 2020 Oct;3(5):612-614. doi: 10.1016/j.euo.2020.08.006. Epub 2020 Sep 4. Eur Urol Oncol. 2020. PMID: 32893185 No abstract available.
Similar articles
-
The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.BMC Cancer. 2024 Jun 8;24(1):706. doi: 10.1186/s12885-024-12388-2. BMC Cancer. 2024. PMID: 38851712 Free PMC article.
-
PARP inhibitors in prostate cancer: practical guidance for busy clinicians.Clin Adv Hematol Oncol. 2020 Dec;18(12):808-815. Clin Adv Hematol Oncol. 2020. PMID: 33406057 Review.
-
Olaparib for the treatment of metastatic prostate cancer.Future Oncol. 2021 Jul;17(19):2413-2429. doi: 10.2217/fon-2020-1245. Epub 2021 Mar 26. Future Oncol. 2021. PMID: 33769071 Review.
-
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28. Oncologist. 2016. PMID: 27022037 Free PMC article. Review.
-
Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer.Curr Oncol Rep. 2022 Nov;24(11):1619-1631. doi: 10.1007/s11912-022-01305-0. Epub 2022 Aug 6. Curr Oncol Rep. 2022. PMID: 35931885 Review.
Cited by
-
The yin and yang of chromosomal instability in prostate cancer.Nat Rev Urol. 2024 Jun;21(6):357-372. doi: 10.1038/s41585-023-00845-9. Epub 2024 Feb 2. Nat Rev Urol. 2024. PMID: 38307951 Review.
-
Germline DNA Damage Response Gene Mutations in Localized Prostate Cancer.Medicina (Kaunas). 2023 Dec 30;60(1):73. doi: 10.3390/medicina60010073. Medicina (Kaunas). 2023. PMID: 38256334 Free PMC article.
-
A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.Diagn Pathol. 2024 Jan 6;19(1):9. doi: 10.1186/s13000-023-01431-8. Diagn Pathol. 2024. PMID: 38184614 Free PMC article.
-
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles.Cell Rep Med. 2023 Dec 19;4(12):101344. doi: 10.1016/j.xcrm.2023.101344. Cell Rep Med. 2023. PMID: 38118421 Free PMC article.
-
Biomarkers for Prostate Cancer: From Diagnosis to Treatment.Diagnostics (Basel). 2023 Oct 31;13(21):3350. doi: 10.3390/diagnostics13213350. Diagnostics (Basel). 2023. PMID: 37958246 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous